Full Text View
Tabular View
No Study Results Posted
Related Studies
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
This study has been completed.
Study NCT00082914   Information provided by National Cancer Institute (NCI)
First Received: May 14, 2004   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Cancer
Melanoma (Skin)
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Kidney Neoplasms
Melanoma
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
denileukin diftitox
Additional drug interventions recognized in this trial
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services